Tarsus Pharmaceuticals Inc (TARS) News

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission...

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered...

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission...

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Tarsus to Participate at Upcoming Investor Conferences

IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission...

Form 8-K - Current report

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and...

Form 8-K - Current report